A real world study assessing the effect of delaying Nintedanib initiation on all-cause medical costs and Idiopathic Pulmonary Fibrosis related hospitalizations
Latest Information Update: 27 Jun 2021
At a glance
- Drugs Nintedanib (Primary)
- Indications Idiopathic pulmonary fibrosis
- Focus Therapeutic Use
- 27 Jun 2021 New trial record
- 19 May 2021 Results presented at the 117th International Conference of the American Thoracic Society